The project "Horizon of excellence in applications of matrix RNA in immuno-oncology HERO" has been allocated PLN 70 million. They will be awarded to the researchers from the largest research centers in Poland, including the Medical University of Warsaw. The project has been recognized by an international group of experts for its great scientific and commercialization potential. The project's key personnel are also rated very highly. Its members have numerous achievements related to scientific activity and its commercialization.
The team consisted of Prof. Andrzej Dziembowski (project leader), Prof. Marta Miączyńska and Prof. Marcin Nowotny from the International Institute of Molecular and Cell Biology, Prof. Jacek Jemielity from the Center for New Technologies of the University of Warsaw, Joanna Kowalska, MD, PhD, from the Faculty of Physics of the University of Warsaw, Prof. Dominika Nowis from the Laboratory of Experimental Medicine of the University of Warsaw, Prof. Jakub Gołąb from the Department of Immunology of the University of Warsaw, and Prof. Robert Hołyst from the Institute of Physical Chemistry of the Polish Academy of Sciences. The researchers aim to create new technologies to increase the stability and translational potential of ribonucleic acid (mRNA) used in cancer immunotherapy. The researchers from our university will evaluate the efficacy of modified mRNAs in preclinical cancer models.
- This is a strategic project for us, which will enable us to focus the scientific work of the Laboratory of Experimental Medicine and the Department of Immunology of our University on one of the most dynamically developing areas of medicine," emphasizes Prof. Gołąb.
The funding will go to the researchers at the Virtual Research Institute (WIB). The institute is an innovative national formula for conducting research that has high potential for socio-economic applications. Funds for the WIB come from the Fund for Polish Science.
